Join
Live feed
·
PRReleasevia Quantisnow
BioVie Inc. logo

BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025)

ByQuantisnow·Wall Street's wire, on your screen.
BIVI· BioVie Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BIVI (BioVie Inc.) and more on Quantisnow.